Imatinib mesylate reduces GIST cell proliferation by binding to the catalytic pocket of the KIT protein product (Schindler et al, 2000), and serves as a hallmark representative for the emerging generation of cancer drugs that selectively inhibits the activity of cancer causing genes or their protein products. Here, KIT is linked to gastrointestinal stromal tumor.